On February 28, 2022, Hemostemix Inc. closed the transaction. The company has issued 8,606,071 units at a price of CAD 0.14 per unit for gross proceeds of up to CAD 1,204,849.92. The company has paid CAD 44,362.39 as finder's fees and issued 316,874 finder's options in the transaction.

The TSX Venture Exchange has accepted for filing documentation with respect to the transaction. The transaction included participation from 42 placees included Thomas Smeenk, President & CEO of company for 700,000 unit, and 3 pro group participation from 533,000 unit.